Kestra Medical Technologies, Ltd. $KMTS Shares Bought by Next Century Growth Investors LLC

Posted by Brian Himes on Jun 14th, 2026

Next Century Growth Investors LLC raised its stake in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Free Report) by 154.5% in the fourth quarter, HoldingsChannel reports. The fund owned 465,845 shares of the company’s stock after purchasing an additional 282,832 shares during the period. Next Century Growth Investors LLC’s holdings in Kestra Medical Technologies were worth $12,354,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Eventide Asset Management LLC lifted its holdings in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after acquiring an additional 65,288 shares during the period. Barclays PLC lifted its holdings in Kestra Medical Technologies by 120.6% in the fourth quarter. Barclays PLC now owns 41,170 shares of the company’s stock valued at $1,092,000 after acquiring an additional 22,507 shares during the period. Brown Advisory Inc. lifted its holdings in Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after acquiring an additional 428,996 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Kestra Medical Technologies by 64.7% in the fourth quarter. The Manufacturers Life Insurance Company now owns 86,784 shares of the company’s stock valued at $2,337,000 after acquiring an additional 34,091 shares during the period. Finally, Walleye Capital LLC increased its position in shares of Kestra Medical Technologies by 502.3% in the fourth quarter. Walleye Capital LLC now owns 53,231 shares of the company’s stock valued at $1,412,000 after buying an additional 44,393 shares in the last quarter.

Kestra Medical Technologies Stock Up 3.5%

Kestra Medical Technologies stock opened at $20.85 on Friday. The stock has a market capitalization of $1.22 billion, a PE ratio of -5.27 and a beta of 0.83. Kestra Medical Technologies, Ltd. has a 12 month low of $13.25 and a 12 month high of $30.00. The business has a 50 day simple moving average of $20.70 and a 200-day simple moving average of $23.10. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The business had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. Kestra Medical Technologies’s revenue was up 62.7% compared to the same quarter last year. On average, analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current fiscal year.

Insider Activity at Kestra Medical Technologies

In related news, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $20.96, for a total transaction of $314,400.00. Following the completion of the sale, the insider directly owned 334,786 shares in the company, valued at approximately $7,017,114.56. The trade was a 4.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 45,000 shares of company stock worth $919,050 in the last three months. 3.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on KMTS. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd. BTIG Research restated a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Finally, The Goldman Sachs Group cut their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Kestra Medical Technologies presently has a consensus rating of “Hold” and an average price target of $27.40.

Read Our Latest Report on KMTS

Kestra Medical Technologies Profile

(Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.